Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 30;9:5097. doi: 10.1038/s41467-018-07603-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Processing pathway of the ppCT_9–17, ppCT_50–59 and ppCT_91–100 epitopes. a Processing of pCT_9–17, ppCT_50–59 and ppCT_91–100 peptides is proteasome dependent. IGR-Heu or IGR-Heu-TAP cells were incubated in the absence or presence of the proteasome inhibitor epoxomicin, and then the generated epitope-specific CTLs were added. Cytotoxic activity was determined by the ⁵¹Cr-release assay at the indicated E:T ratios. Values correspond to means (±SD) of percentages of lysis from triplicates. b Production of IFN-γ by patient 1’s T cell clones or cloids stimulated with autologous ppCT-expressing tumour cell lines. Anti-ppCT peptide T cells were stimulated for 36 h with IGR-Heu-TAP (anti-ppCT_9–17, -ppCT_50–59 and -ppCT_91–100) or IGR-Heu (anti-ppCT_16–25) tumour cells, untreated or pretreated with epoxomicin or DCI; then IFN-γ production was measured by ELISA. Data shown are means (±SD) of three T cell clones and T cell cloids from three independent experiments. c Involvement of SP in processing of ppCT_9–17, ppCT_50–59 and ppCT_91–100 antigenic peptides. IGR-Heu-TAP tumour cells were incubated with SP inhibitor DCI before addition of anti-ppCT epitope CTLs. Cytotoxicity of anti-ppCT_16–25 CTLs towards IGR-Heu tumour cells, untreated or pretreated with DCI, was included. d Processing of the ppCT_9–17 epitope involves SPP. The lytic activity of ppCT_9–17-, ppCT_50–59- and ppCT_91–100-specific CTLs against IGR-Heu-TAP, electroporated with siRNA targeting SPP (siRNA SPP) or siRNA control (siRNA Crtl), was examined as in a. e Processing of ppCT_50–59- and ppCT_91–100 epitopes is ERAD dependent. IGR-Heu and IGR-Heu-TAP tumour cells were incubated in the absence or presence of EER1, and then epitope-specific CTLs were added. Values correspond to means (±SD) of percentage of lysis from triplicates. Data shown are from two independent experiments out of three. *p < 0.05; **p < 0.01; ***p < 0.001 (two-tailed Student’s unpaired t test). Blue: patient 1, red: patient 13 and green: patient 3. DCI dichloroisocoumarin, EER1 eeyarestatin 1, E:T effector:target